EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Klotho Neurosciences's Enterprise Value is $57.86 Mil.
Klotho Neurosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was $-5.55 Mil. Therefore, Klotho Neurosciences's EV-to-FCF for today is -10.42.
The historical rank and industry rank for Klotho Neurosciences's EV-to-FCF or its related term are showing as below:
KLTO'
s EV-to-FCF Range Over the Past 10 Years
Min: -10.42 Med: 0 Max: 0
Current: -10.42
KLTO's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 16.48
vs KLTO: -10.42
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Klotho Neurosciences's PE Ratio (TTM) for today is calculated as:
Klotho Neurosciences's share price for today is $0.5242.
Klotho Neurosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Klotho Neurosciences EV-to-FCF Related Terms
Klotho Neurosciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Klotho Neurosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Klotho Neurosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klotho Neurosciences EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Klotho Neurosciences's EV-to-FCF falls into.
Klotho Neurosciences's current Enterprise Value is $57.86 Mil.
Klotho Neurosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Klotho Neurosciences (KLTO) has a EV-to-FCF of -10.42 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Klotho Neurosciences and its competitors.
Is Klotho Neurosciences' EV-to-FCF too high?
Klotho Neurosciences' current EV-to-FCF is -10.42. Overall, Klotho Neurosciences has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Klotho Neurosciences' EV-to-FCF compare to KTTA and JUNS?
Klotho Neurosciences' EV-to-FCF of -10.42 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 16.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.48, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Klotho Neurosciences and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klotho Neurosciences's current EV-to-FCF is -10.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klotho Neurosciences stock overvalued right now?
Klotho Neurosciences (KLTO) has a current EV-to-FCF of -10.42. The current EV-to-FCF is -10.42. Klotho Neurosciences' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Klotho Neurosciences (KLTO), the current EV-to-FCF is -10.42 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
22GF Score
Get the complete analysis for KLTO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLTO has been successfully added to your 
